Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Liver International : Official Journal of the International Association for the Study of the Liver|November 18, 2021
Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinomaJaekyung Cheon, Changhoon Yoo, Jung Yong Hong, et al.
Oncology Reports|May 14, 2016
Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cellsHye-Sook Seo, Jin Mo Ku, Han-Seok Choi, et al.
The Lancet. Oncology|October 17, 2021
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b studyChanghoon Yoo, Kyu-Pyo Kim, Jae Ho Jeong, et al.
JHEP Reports : Innovation in Hepatology|March 3, 2023
High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinomaHannah Yang, Beodeul Kang, Yeonjung Ha, et al.
Journal of Hepatology|March 27, 2025
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trialsChanghoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Journal of Cancer|March 14, 2022
A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancerSejin Kim, Bum Jun Kim, Ilhwan Kim, et al.
JAMA Oncology|March 23, 2023
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical TrialJaewon Hyung, Ilhwan Kim, Kyu-Pyo Kim, et al.
Liver Cancer|May 29, 2026
Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter StudyJung Sun Kim, San-Chi Chen, Jeffrey Sum Lung Wong, et al.
Cancer Medicine|June 9, 2025
Organ-Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective StudyJung Sun Kim, Youngun Kim, Beodeul Kang, et al.
Future Oncology (London, England)|July 29, 2022
Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenibDong-Hoon Lim, Andrea Casadei-Gardini, Myung Ah Lee, et al.
Pageof 4